Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome

Movement Disorders

Volumn 27, Issue 2, 2012, Pages 312-315

  Winder Rhodes, Sophie E ^a   Garcia Reitböck, Pablo ^a,b   Ban, Maria ^a   Evans, Jonathan R ^a   Jacques, Thomas S ^c   Kemppinen, Anu ^a   Foltynie, Thomas ^d   Williams Gray, Caroline H ^a   Chinnery, Patrick F ^d   Hudson, Gavin ^e   Burn, David J ^d   Allcock, Liesl M ^e   Sawcer, Stephen J ^a   Barker, Roger A ^a   Spillantini, Maria Grazia ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Alpha synuclein; Genetics; Lysosomal disorders; Parkinson's disease; Sanfilippo syndrome

Indexed keywords

ALPHA SYNUCLEIN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC LINKAGE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; SANFILIPPO SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM;

ACETYLGLUCOSAMINIDASE; AGED; ALPHA-SYNUCLEIN; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUCOPOLYSACCHARIDOSIS III; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84856955519     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24029     Document Type: Article

References (20)

1. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006; 5: 235-245.
2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature. 1997; 388: 839-840.
3. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009; 18: R48-R59.
4. Spencer CCA, Plagnol V, Strange A, et al. Dissection of the genetics of Parkinson's disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet. 2011; 20: 345-353.
5. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol. 2007; 62: 145-153.
6. Sidransky E, Nalls MA, Aasly JO et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009; 361: 1651-1661.
7. Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep. 2010; 10: 190-198.
8. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009; 132: 1783-1794.
9. Shachar T, Bianco CL, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov Disord. 2011; 26: 1593-1604.
10. Valstar MJ, Ruijter GJG, Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: A mini-review. J Inherit Metab Dis. 2008; 31: 240-252.
11. Hamano K, Hayashi M, Shioda K, Fukatsu R, Mizutani S. Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue. Acta Neuropathol. 2008; 115: 547-559.
12. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered. 2008; 66: 87-98.
13. Garcia-Reitbock P, Anichtchik O, Bellucci A, et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain. 2010; 133: 2032-2044.
14. Settembre C, Fraldi A, Jahreiss L, et al. A block of autophagy in lysosomal storage disorders. Hum Mol Genet. 2008; 17: 119-129.
15. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003; 278: 25009-25013.
16. Tong Y, Yamaguchi H, Giaime E, et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of a-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci. 2010; 107: 9879-9884.
17. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron. 2003; 37: 583-595.
18. Walkley SU, Vanier MT. Secondary lipid accumulation in lysosomal disease. Biochim Biophys Acta Mol Cell Res. 2009; 1793: 726-736.
19. Sharon R, Bar-Joseph I, Mirick GE, Serhan CN, Selkoe DJ. Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem. 2003; 278: 49874-49881.
20. Barnett MW, Fisher CE, Perona-Wright G, Davies JA. Signalling by glial cell line-derived neurotrophic factor (GDNF) requires heparan sulphate glycosaminoglycan. J Cell Sci. 2002; 115: 4495-4503.